Neurocrine Biosciences (NBIX) EBIAT (2016 - 2025)
Neurocrine Biosciences (NBIX) has disclosed EBIAT for 15 consecutive years, with $153.7 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT rose 49.08% year-over-year to $153.7 million, compared with a TTM value of $478.6 million through Dec 2025, up 40.23%, and an annual FY2025 reading of $478.6 million, up 40.23% over the prior year.
- EBIAT was $153.7 million for Q4 2025 at Neurocrine Biosciences, down from $209.5 million in the prior quarter.
- Across five years, EBIAT topped out at $209.5 million in Q3 2025 and bottomed at -$76.6 million in Q1 2023.
- Average EBIAT over 4 years is $77.8 million, with a median of $83.1 million recorded in 2023.
- The sharpest move saw EBIAT surged 156.66% in 2024, then tumbled 81.8% in 2025.
- Year by year, EBIAT stood at $22.5 million in 2021, then skyrocketed by 556.44% to $147.7 million in 2023, then tumbled by 30.2% to $103.1 million in 2024, then skyrocketed by 49.08% to $153.7 million in 2025.
- Business Quant data shows EBIAT for NBIX at $153.7 million in Q4 2025, $209.5 million in Q3 2025, and $107.5 million in Q2 2025.